While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
Updated: Apr 7, 2017 at 12:29PM
Published: Oct 6, 2012 at 12:00AM
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings... Follow @motleydavid
Today Fool.com health-care analysts David Williamson and Max Macaluso look at one of the largest and most profitable segments of the pharmaceutical space: diabetes treatment.
With the market growing rapidly, it's attracted a lot of attention from big pharma companies, and the pressure to improve treatments is heating up.
Merck is attempting to hold on to market share for now, but Amalin's technology has the potential to upset the standing king. Ultimately, David thinks Merck will still be able to retain its throne but recognizes that the stakes are heating up.
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 04/12/2021.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return